We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies
Product News

OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies

OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies
Product News

OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OriGene Announces the Release of Specificity-Verified UltraMAB™ Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OriGene Technologies has announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB™ brand.

UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein Microarray Technology.

OriGene's 10K High Density Protein Microarray Platform enables the screening of candidate antibodies against greater than 10,000 human proteins to identify the most specific monoclonal antibodies for IHC applications.

"High-specificity is the pre-requisite for any IHC antibody because IHC detection relies on only one antibody against a complex tissue sample. Through the use of novel and proprietary technologies such as our 10K High-Density Protein Microarray Platform, OriGene has dramatically improved the specificity of antibodies available to the global market place. By validating all UltraMAB antibodies against our 10K High-Density Protein Microarray Platform, the market now has access to one of the industry's most significant tools for IHC detection and determination of accurate results," said Dr. Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

Each UltraMAB™ is validated for IHC and for immunoassay analysis, and determined to have no cross-reactivity with other human proteins other than the antibody's intended target protein as determined by OriGene's 10K High Density Protein Microarray Platform.

Consequently, each UltraMAB™ is quality control verified, guaranteeing superior performance for IHC applications, where specificity-verification and the highest quality antibodies are critical for accurate detection.

Detailed information about the UltraMAB™ Antibodies is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to monoclonal antibody development and contact the company's representatives to explore collaborative opportunities.

Advertisement